Keywords (1)

Academic
Publications
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications

Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications,10.1200/JCO.2005.18.853,Journal of Clinical Oncology,R. S. Herbst

Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications   (Citations: 70)
BibTex | RIS | RefWorks Download
Journal: Journal of Clinical Oncology - J CLIN ONCOL , vol. 23, no. 14, pp. 3243-3256, 2005
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...A number of anti-angiogenic agents with anti-angiogenic and anti-tumor activity, including a tyrosine kinase inhibitor (TKI), are currently in development [5-8]...

    She-Juan Anet al. The -271 G>A polymorphism of kinase insert domain-containing receptor ...

    • ...These drugs inhibit angiogenesis in various standardized assays, and the molecular mechanism appears to be via effects on endothelial cell phospholipids [25]...

    Kelly L. Snideret al. Cardiovascular toxicities: clues to optimal administration of vascular...

    • ...In particular, high vascularity at the tumor periphery has been correlated with tumor progression [14]...
    • ...Initiation of angiogenesis is believed to rely on an angiogenic “switch” [14] that includes the secretion of angiogenic factors by tumors and their precursor cells [15]...
    • ...High VEGF levels have been identified as an independent prognostic factor correlated with poor prognosis in patients with lung cancer [14]...
    • ...High expression of bFGF is also an independent indicator of poor outcome in NSCLC patients [14]...
    • ...In NSCLC, increased PDEC-GF/TP expression correlates with a higher vascular grade and poorer prognosis in patients with node-negative disease [9,14]...
    • ...Expression of both factors was found in NSCLC tissue samples, with HIF-2α considered to be an independent prognostic indicator of poor outcome [14]...
    • ...The small-molecule TKIs prevent activation of VEGF receptors [14] through binding to the ATP pocket of their TK residues in the intracellular domain [16]...
    • ...Its role in patients with lung cancer is being evaluated in a phase II study (the GOAL Study) designed to evaluate the efficacy of PTK/ZK in patients with stage IIIB/IV NSCLC [14]...

    S N Metodieva. Angiogenesis and Non Small Cell Lung Cancer

    • ... When the stimulatory factors exceed the inhibitory factors an ‘angiogenic switch’ occurs, and a cascade of events is initiated, including the release of proangiogenic stimulatory factors, endothelial cell activation, endothelial cell migration, proliferation and capillary tube formation (...

    T E Stinchcombeet al. Bevacizumab in the treatment of non-small-cell lung cancer

Sort by: